Hyaluronate–Flt1 peptide conjugate/epirubicin micelles for theranostic application to liver cancers

Cancer theranostic systems using polymeric micelles are emerging for simultaneous diagnosis and therapy. In this work, we have developed hyaluronate (HA)-Flt1 peptide conjugate micelles encapsulating epirubicin for theranostic treatment of hepatocellular carcinoma. Intravital bioimaging without labelling and in vivo anti-tumor therapeutic effect clearly confirmed the feasibility of HA-Flt1 peptide conjugate/epirubicin micelles for target-specific theranostic treatment of liver cancers.